Methergin (Methylergometrine Maleate)

Methylergometrine Maleate acts as a partial agonist at serotonin (5‑HT2), alpha‑adrenergic and dopamine receptors in uterine smooth muscle. This receptor activity increases muscle tone and induces rhythmic contractions, promoting uterine contraction and facilitating hemostasis after delivery.

The dose of Methergin is determined by the prescribing obstetrician or qualified healthcare professional based on the clinical situation. Dosage may vary according to the severity of hemorrhage, route of administration (intramuscular or intravenous), and patient-specific factors.

Methergin is intended for use in the immediate postpartum period, after delivery. Its safety profile for use during pregnancy is not established, and it is generally not administered before birth. Breastfeeding considerations should be discussed with a healthcare provider.

To order Methergin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Methergin belongs to the ergot alkaloid class, offering a different receptor profile compared with oxytocin or misoprostol. It provides a longer duration of uterine contraction but may have a higher risk of vasospastic side effects. Choice of agent depends on clinical guidelines, patient risk factors and provider preference.

Methergin should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Methergin is supplied as an injectable solution for intramuscular or intravenous administration. The injection is typically given by a qualified healthcare professional in a controlled obstetric setting, following aseptic technique and appropriate dosing guidelines.

Serious risks include severe hypertension, coronary artery spasm leading to myocardial ischemia, seizures, pulmonary edema, and rare anaphylactic reactions. Patients should be closely monitored for cardiovascular signs and any adverse neurological symptoms during and after administration.

Methergin should be avoided in patients with known hypersensitivity to ergot alkaloids, existing severe hypertension, coronary artery disease, or a history of vasospastic disorders. It is also contraindicated in individuals taking monoamine oxidase inhibitors.